Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses

Keyphrases

• Acute Treatment 100%
• Antipsychotics 100%
• Network Meta-analysis 100%
• Haloperidol 100%
• First-episode Psychosis 100%
• Risperidone 83%
• Olanzapine 83%
• Standardized Mean Difference 50%
• Randomized Controlled Trial 33%
• Weight Gain 33%
• Drug Use 33%
• Quetiapine 33%
• Negative Symptoms 33%
• Second-generation Antipsychotics 33%
• Amisulpride 33%
• Prolactin Release 33%
• Parkinsonian Symptoms 33%
• Quality of Life 16%
• MEDLINE 16%
• Cochrane Library 16%
• Meta-analysis 16%
• Illness 16%
• Ministry of Education 16%
• PubMed 16%
• Odds Ratio 16%
• Treatment Options 16%
• Low-to-moderate 16%
• Sub-optimum 16%
• Embase 16%
• Dropout 16%
• Treatment Choice 16%
• Tolerability 16%
• Response to Treatment 16%
• Sedation 16%
• Treatment Study 16%
• Random Effects Model 16%
• PsycINFO 16%
• Treatment Use 16%
• Indirect Comparison 16%
• Positive Symptoms 16%
• Ziprasidone 16%
• Akathisia 16%
• Aripiprazole 16%
• Inefficacy 16%
• Categorical Response 16%
• All-cause Discontinuation 16%
• Overall Functioning 16%
• Molindone 16%
• Number of Patients 16%

Neuroscience

• Meta-Analysis 100%
• Haloperidol 100%
• Antipsychotic 100%
• Risperidone 83%
• Olanzapine 83%
• Randomized Controlled Trial 33%
• Prolactin 33%
• Quetiapine 33%
• Amisulpride 33%
• Negative Syndrome 33%
• Aripiprazole 16%
• Ziprasidone 16%
• Molindone 16%
• Positive Syndrome 16%
• Akathisia 16%

Pharmacology, Toxicology and Pharmaceutical Science

• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 100%
• Antipsychotic Drug 100%
• Risperidone 83%
• Olanzapine 83%
• Randomized Controlled Trial 33%
• Quetiapine 33%
• Negative Syndrome 33%
• Amisulpride 33%
• Prolactin 33%
• Tolerability 16%
• Random Effects Model 16%
• Aripiprazole 16%
• Side Effect 16%
• Ziprasidone 16%
• Positive Syndrome 16%
• Molindone 16%
• Akathisia 16%
• Diseases 16%